The constructed NA-FGF-N-2-HACC/CMCS MPs can be used as a novel drug agent to replace traditional insulin-based therapy in the treatment of type 2 diabetes and provide a theoretical basis for addressing insulin resistance. This evidence concerns the gene INS and Insulin resistance.